Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019...
LOS ANGELES--(BUSINESS WIRE)--Dec 11, 2019-- |!| Oelwein
LOS ANGELES--(BUSINESS WIRE)--Dec 11, 2019-- |!| Oelwein